Related Experiment Video
Updated: May 25, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Approach to lipid therapy in the patient with atherosclerotic vascular disease
1Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, 02115, USA, rpande@partners.org.
Insights
Hyperlipidemia, or high cholesterol, significantly raises the risk of atherosclerotic vascular disease and recurrent cardiovascular events. Statins effectively lower low-density lipoprotein (LDL) cholesterol, reducing these risks.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hyperlipidemia is a major risk factor for atherosclerotic vascular disease and cardiovascular events.
- Elevated low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides, along with low high-density lipoprotein (HDL) levels, are linked to coronary heart disease.
- Lowering LDL cholesterol with statins has been proven to reduce recurrent cardiovascular events by approximately 25%.
Purpose of the Study:
- To review the role of lipid-lowering therapies in managing atherosclerotic vascular disease.
- To discuss the efficacy of statins and other lipid-modifying agents.
- To outline therapeutic goals for cholesterol management in high-risk patients.
Main Methods:
- Review of large population studies and landmark clinical trials.
- Analysis of evidence supporting statin therapy for LDL cholesterol reduction.
- Examination of second-line lipid-lowering medications.
Main Results:
- Statins significantly reduce recurrent cardiovascular events.
- The benefits of altering non-LDL cholesterol levels (triglycerides, HDL) are less established.
- Lifestyle modifications are a cornerstone of first-line therapy.
Conclusions:
- Statins are the first-line treatment for lipid lowering in patients with atherosclerotic vascular disease.
- Achieving target LDL cholesterol levels (<100 mg/dL or <70 mg/dL for high-risk individuals) is crucial.
- Combination therapy with other agents may be considered for comprehensive lipid management.
Opinion Statement:
Hyperlipidemia increases the incidence of atherosclerotic vascular disease and is associated with greater rates of recurrent cardiovascular events among individuals with established vascular disease. Several large population studies have confirmed the link between all cholesterol components (including elevated low-density lipoprotein [LDL] cholesterol, total cholesterol, and triglyceride levels, and reduced high-density lipoprotein [HDL] levels) with coronary heart disease and other manifestations of systemic atherosclerosis. In addition, landmark clinical trials have clearly established that lowering LDL cholesterol levels with statins (HMG-CoA reductase inhibitors) can lower recurrent cardiovascular events by nearly 25%. The benefits of altering non-LDL cholesterol levels (eg, triglycerides and HDL) are less clear, but several other medications are often used in conjunction with statins for cholesterol lowering. First-line therapy for lipid lowering in patients with atherosclerotic vascular disease includes statins and a recommendation for lifestyle changes (including diet and exercise). Second-line options for lowering cholesterol include fibrates, nicotinic acid, bile acid sequestrants, and ezetimibe. Therapeutic goals for patients with vascular disease are to achieve an LDL cholesterol level < 100 mg/dL, or <70 mg/dL in individuals at particularly high risk.
Related Concept Videos
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Atherosclerosis I: Introduction
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management